Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: Final results of a phase II trial (CALGB 50501)

CALGB designed a phase II trial of lenalidomide+bortezomib for relapsed/refractory mantle cell lymphoma (MCL). Induction therapy was lenalidomide (days 1-14) plus bortezomib (days 1/4/8/11), every 21 days for eight cycles. Complete and partial responders (CR, PR) received maintenance lenalidomide (d...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Leuk Lymphoma
Main Authors: Morrison, Vicki A., Jung, Sin-Ho, Johnson, Jeffrey, LaCasce, Ann, Blum, Kristie A., Bartlett, Nancy L., Pitcher, Brandelyn N., Cheson, Bruce D.
Format: Artigo
Sprog:Inglês
Udgivet: 2014
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4725701/
https://ncbi.nlm.nih.gov/pubmed/24996441
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2014.938333
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker